Evidence Into Practice:<i>Prescribing Selective Serotonin Reuptake Inhibitors</i>
International Journal of Technology Assessment in Health CarePublished 1 January 1998
Nick Freemantle, James Mason, Ian Watt
Citations6
SJR quartileQ2
SJR score0.85
SNIP0.87
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
It is found that simple distribution of the results of health technology assessments may not be sufficient to influence practice, and prescribing trends seem unaffected by the release of information on the effectiveness and costeffectiveness of antidepressant drugs.
Abstract
This descriptive analysis examines prescribing trends of antidepressants in English primary care, providing analysis of NHS reimbursement data for groups of antidepressants between 1989 and 1994. Prescribing trends seem unaffected by the release of information on the effectiveness and cost-effectiveness of antidepressant drugs. We found that simple distribution of the results of health technology assessments may not be sufficient to influence practice.
Keywords
PsychologyHealth ProfessionsEconomics, Econometrics and Finance
BMJSelective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability.
401 Citations1993Fujian Song, Nick Freemantle +5 more
Routine use of selective serotonin reuptake inhibitors as the first line treatment of depressive illness may greatly increase cost with only questionable benefit, according to meta-analysis of 63 randomised controlled trials.
International Clinical PsychopharmacologySelective serotonin reuptake inhibitors
256 Citations1994S.A. Montgomery, J.A. Henry +6 more
There is a significant and clinically important advantage for the SSRIs compared with the TCAs in the acceptability of treatment measured by the number of discontinuations due to side effects reported in published studies.
The British Journal of PsychiatryWhat Price Depression?
228 Citations1994Bengt Jönsson, Paul Bebbington
The model reveals that medication that appears expensive in terms of cost per day may not be so when patient compliance and the total costs of treatment are taken into account.
BMJPrescribing selective serotonin reuptake inhibitors as strategy for prevention of suicide
100 Citations1994Nick Freemantle, Allan House +3 more
The cost per life year gained through avoiding suicides by the routine first line use of serotonin reuptake inhibitors is likely to be high and the shift to considerably more expensive options must be further investigated.
BMJLessons from international experience in controlling pharmaceutical expenditure III: regulating industry: Table 1
69 Citations1996Karen Bloor, Alan Maynard +1 more
Policy regulating the supply of drugs, particularly licensing and reimbursement controls, price and profit regulation, is reviewed, finding that carefully monitored economic evaluation could lead to improvements in efficiency and benefits to patients and the health care system.
BMJMeasuring prescribing: the shortcomings of the item
58 Citations1994Stephen Bogle, Conrad M. Harris
The item is unsuitable as a measure of prescribing volume, even at regional level: a new measure, based on standard daily dosages, is needed.
BMJ Quality & SafetyImplementing findings of medical research: the Cochrane Collaboration on Effective Professional Practice.
54 Citations1995Nick Freemantle, Roberto Grilli +2 more
The aim of the recently formed Cochrane Collaboration on Effective Professional Practice is to undertake and maintain systematic reviews of rigorous research which evaluate methods of promoting effective professional practice and to make these reviews available to relevant decision makers.
BMJPromoting cost effective prescribing
43 Citations1995Nick Freemantle, David Henry +2 more
The message is clear: doctors may prescribe an effective drug to patients who will benefit, but if the drug is not cost effective they may be using resources that would produce greater benefit for other patients for the same cost.
BMJBenefits of new drugs are exaggerated
24 Citations1994David Owens
Interest is shifting towards other clinical situations and claims that serotonin reuptake inhibitors are ideal for severe depression, resistant depression, continuing treatment, prophylaxis, and so on are soon being treated.
Drug and Therapeutics BulletinSelective serotonin reuptake inhibitors for depression?
22 Citations1993
In the past decade a new class of drugs, the selective serotonin reuptake inhibitors (SSRIs), has become available for the treatment of patients with depressive illness, and how do they compare with the older and cheaper tricyclics?
BMJControversies in Management: New or old antidepressants? New is better
21 Citations1994Gillian Harrison
There is no evidence that the "new" antidepressants, such as lofepramine and the selective serotonin reuptake inhibitors, are any more effective than older treatments, but they are certainly equally effective.
Journal of Management in MedicineAn Initial Evaluation of Effective Health Care Bulletins as Instruments of Effective Dissemination
6 Citations1993Sue Ibbotson, Andrew Long +2 more
Confidence to act was strongly correlated with a stated intention to use the bulletin in situations relating to the purchase of bone density screening for osteoporosis and also with the view that the bulletin would be influential in local discussions, and further research is needed to assess the impact on decision making.